Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
40.83%
operating margin TTM
-103.89%
revenue TTM
40.79 Million
revenue per share TTM
0.72$
valuation ratios | |
|---|---|
| pe ratio | 14.86 |
| peg ratio | 0.01 |
| price to book ratio | 3.84 |
| price to sales ratio | 6.10 |
| enterprise value multiple | 7.54 |
| price fair value | 3.84 |
profitability ratios | |
|---|---|
| gross profit margin | 80.28% |
| operating profit margin | -103.89% |
| pretax profit margin | 63.57% |
| net profit margin | 40.83% |
| return on assets | 12.76% |
| return on equity | 41.63% |
| return on capital employed | -35.93% |
liquidity ratios | |
|---|---|
| current ratio | 8.62 |
| quick ratio | 8.57 |
| cash ratio | 2.08 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 29.98 |
| operating cycle | 102.82 |
| days of payables outstanding | 242.82 |
| cash conversion cycle | -140.00 |
| receivables turnover | 5.01 |
| payables turnover | 1.50 |
| inventory turnover | 12.17 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.23 |
| debt equity ratio | 0.47 |
| long term debt to capitalization | 0.32 |
| total debt to capitalization | 0.32 |
| interest coverage | -10.66 |
| cash flow to debt ratio | -0.37 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.43 |
| cash per share | 3.57 |
| operating cash flow per share | -0.42 |
| free cash flow operating cash flow ratio | 1.04 |
| cash flow coverage ratios | -0.37 |
| short term coverage ratios | -52.98 |
| capital expenditure coverage ratio | -26.98 |
Frequently Asked Questions
When was the last time Zevra Therapeutics, Inc. (NASDAQ:ZVRA) reported earnings?
Zevra Therapeutics, Inc. (ZVRA) published its most recent earnings results on 05-11-2025.
What is Zevra Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Zevra Therapeutics, Inc. (NASDAQ:ZVRA)'s trailing twelve months ROE is 41.63%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Zevra Therapeutics, Inc. (ZVRA) currently has a ROA of 12.76%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ZVRA's net profit margin stand at?
ZVRA reported a profit margin of 40.83% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ZVRA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 8.62 in the most recent quarter. The quick ratio stood at 8.57, with a Debt/Eq ratio of 0.47.